Kornimate/medical-research-clean huggingface dataset:
intra-operative rapid identification of lymph node and parathyroid

Conditions: Thyroid Cancer; Parathyroid; Absent; Hypocalcemia; Hypoparathyroidism Postprocedural

Summary: during surgery, a fine needle puncture was proceeded when suspicious nodes was found by clinician. repeat the punction for 2-3 times from different orientation and then, diff-quik staining or pth immunochromatographic assay were proceeded for lymph node or parathyroid glands identification. post-operative pathology outcome was considered as golden standard.

in the experiment group, when suspicious parathyroid glands or lymph nodes were observed, a 22 g needle was applied for in situ puncture at a 45 degree angle. the needle was initially thrust into the gland for 0.2 mm, and then we advanced the needle for another 0.2mm while gently withdrawing the plunger of the syringe and maintaining negative pressure. at this point, there has parathyroid tissue been adsorbed in the needle. repeat this process in two different directions to guarantee the simple volume. when cell smears finished, the smears were fixed in stationary liquid within 2-4 seconds for 5-20 seconds, and then diff-quik (dq) staining technique was proceeded for rapid identification using diff-quik staining kit according to the instruction. after the following diff-quick staining for 30 seconds, we can make out parathyroid cells and lymph nodes under high power microscope. in addition,pth immunochromatographic assay kit can also be used for parathyroid glands detection. using indicator paper to dip to the punctured tissue, the existance of parathyroid glands could be ensured. he (hematoxylin and eosin) staining was used for pathological verification of suspicious nodes found during surgery. the suspicious nodes occurred in surgery were isolated and fixed with 4% paraformaldehyde for 12 h, embedded in parafﬁn and cut into 3-µm serial sections. corresponding sections were stained with hematoxylin (baso diagnostics inc. zhuhai) for 10 min at room temperature. then, sections were washed with running water. subsequently, sections were washed with scott promote blue liquid for 1 min, 1% hydrochloric acid alcohol differentiation liquid for 20 s, and scott promote blue liquid for 1 min. then, sections were stained with eosin (baso diagnostics inc. zhuhai) for 30 s. sections were washed with running water and sealed for observation. finally, sections were observed by image-pro plus 5.0 software (media cybernetics, inc., bethesda, md, usa).

Eligibility criteria:
inclusion criteria: - thyroid cancer patients undergoing thyroid cancer surgery preoperative examination were all ready for surgery diagnosed with thyroid cancer by fine needle puncture before surgery exclusion criteria: - patients enrolled into another clinical study pregnant patients patients diagnosed with another life-treating disease patients with surgical contraindication

Keywords: parathyroid glands needle puncture diff-quik staining pth test assay thyroid cancer
comparison of the proprioceptive neuromuscular facilitation and mobilization in subacromial impingement syndrome

Conditions: Subacromial Impingement; Subacromial Impingement Syndrome

Summary: aim of the study was to compare the effectiveness of proprioceptive neuromuscular facilitation (pnf) exercises and shoulder mobilization (sm) on pain, range of motion (rom), functionality, and muscle strength in patients with subacromial impingement syndrome (sis). patients received 20 sessions (for 4 weeks) under the supervision of a physiotherapist. patients were evaluated at baseline, at week two, at week four, and at week sixteen.

aim of the study was to compare the effectiveness of proprioceptive neuromuscular facilitation (pnf) exercises and shoulder mobilization (sm) on pain, range of motion (rom), functionality, and muscle strength in patients with subacromial impingement syndrome (sis). forty-four patients were divided into three groups as group i: conventional physiotherapy receiving group (control group; n=14), group ii: conventional physiotherapy + pnf exercises receiving group (pnf group; n=15), and group iii: conventional physiotherapy + sm receiving group (sm group; n=15). pain, rom, muscle strength, and functionality were evaluated by using visual analog scale (vas), goniometer, push-pull dynamometer, constant-murley score and the disabilities of the arm, shoulder and hand (dash) score respectively. patients received 20 sessions in total under supervision of a physiotherapist. patients were evaluated at baseline, at week two, at week four, and at week sixteen.

Eligibility criteria:
inclusion criteria: * aged between 25-65 years old, * having the diagnosis of subacromial impingement syndrome (sis), * having shoulder pain at least for four weeks exclusion criteria: * having a neuromuscular disease, * pregnancy, * history of cancer, * unstable angina, * having pulmonary and/or vascular problems, * history of surgery at neck, shoulder, elbow or/and hand, * having communication problems * having systemic anti-inflammatory joint diseases * being contraindicated for electrical stimulation and/or exercise * having cervical disc herniation or radiculopathy * history of physiotherapy on the same shoulder due to sis, * a history of corticosteroid injection in the last three months, * any orthopedic, rheumatologic, or congenital condition that effects the targeted shoulder

Keywords: proprioceptive neuromuscular facilitation functionality mobilization pnf
the prevalence of malnutrition and sarcopenia in swiss rehabilitation settings

Conditions: Malnutrition; Sarcopenia

Summary: the aim of the study is to identify the prevalence of malnutrition and sarcopenia in patients admitted in swiss rehabilitation centers. furthermore, the aim is to investigate the changes of selected malnutrition and sarcopenia parameters over the length of the rehabilitation stay.

the project aims to investigate the prevalence of malnutrition and sarcopenia in the rehabilitation setting. a cross-sectional national multicenter study will be conducted in five rehabilitation centers in switzerland, including 80 - 130 participants per center for the primary objective (prevalence study). patients will be screened for malnutrition and sarcopenia with established screening tools and if an elevated risk is observed, diagnosis will be confirmed and severity investigated according to international guidelines. furthermore, the evolution of selected malnutrition and sarcopenia parameters over the rehabilitation stay should be assessed.

Eligibility criteria:
inclusion criteria: patients treated in the following groups of rehabilitations will be included: * geriatric rehabilitation * pulmonal rehabilitation * cardiovascular rehabilitation * neurological rehabilitation * musculoskeletal rehabilitation * internistic rehabilitation and oncological rehabilitation exclusion criteria: * inability to give informed consent * inability to follow study procedures (e.g., due to delirium or language barriers) * expected life expectancy \< 3 months and/or palliative care * isolation for example due to covid-19 infection or tuberculosis * severe dehydration/ volume overload * medical conditions that prevent conducting a bioelectrical impedance analysis (bia) measurement (e.g. non-removable plasters or bandages at feet or hands) or defibrillator

Keywords: malnutrition sarcopenia rehabilitation prevalence nutritional risk screening handgrip strength
radial artery puncture hemostasis study

Conditions: Radial Artery Hemostasis

Summary: raphe is an open label randomized clinical trial to assess physical, biological and chemical methods of radial artery puncture hemostasis following coronary catheterization. a total of 600 subjects will be randomized in a 1:1:1 fashion to either the statseal, axiostat or tr band hemostasis devices. follow-up of the subject will take place 60 days after the index procedure.


Eligibility criteria:
inclusion criteria: * coronary angiogram planned from a radial artery approach * use of 5, 6 or 7 french sheaths exclusion criteria: * radial artery diameter \<1.8 mm as measured via ultrasound * established peripheral arterial disease * known autoimmune illness * hemodynamic instability * pregnant or nursing * condition following resuscitation

Keywords: radial artery puncture radial artery occlusion radial artery bleeding
effects of infant egg consumption on child health and cognition development

Conditions: Growth & Development; Obesity; Cardiovascular Risk Factor; Metabolic Syndrome; Food Allergy; Cognitive Developmental Delay

Summary: the objective of this study is to examine how infant egg consumption (age of introduction and frequency of intake) influences physical growth, obesity, cardio-metabolic health, risk of food allergy, and cognition development in mid-childhood and adolescence.

the investigators will use existing data from two us longitudinal birth cohorts that tracked mother-child dyads from pregnancy to adolescence: 1) project viva (1999-present) that enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age, and 2) the infant feeding practices study ii (ifps ii, 2005-2007) that enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (n=2,552) to 12 months of infant age, and at 6 years. for aim 1, the investigators will classify infants based on their age of egg introduction: never, \<2 months, 2-3 months, 4-5 months, 6-8 months, 9-11 months, and 12 months. the investigators will compare physical growth, obesity, cardio-metabolic health, food allergy, and cognition test scores in mid-childhood and adolescence. the investigators will fit multi-variable linear or logistic regression models with fractional polynomial functions of the infant age of egg introduction. both linear (e.g., earlier introduction, a higher probability of the outcome) and non-linear (e.g., threshold effect) associations will be tested. for aim 2, the investigators will classify infants based on their frequency of egg intake: never, \<once/week, once/week, 2-4 times/week, nearly daily or daily, and 2 times/day. the investigators will use similar analytic methods mentioned above to compare their later outcomes. finally, the investigators will create an average probability of multiple child outcomes to balance across different aspects of child health and development. the investigators will identify the lowest-risk infant egg consumption when the corresponding average predicted probability of the related adverse outcomes is the lowest.

Eligibility criteria:
inclusion criteria: * children with complete data on infant egg consumption and the corresponding health and cognition outcomes. exclusion criteria: * none.
evaluation of the alife hera system as an adjunctive tool for the prioritization of embryos deemed suitable for transfer

Conditions: Infertility

Summary: to evaluate the clinical pregnancy rate (pregnancy defined as fetal heartbeat at 6-8 weeks) with the adjunctive use of the hera system (hera system used with traditional morphological grading) with embryos already deemed suitable for transfer compared to trained embryologists using standard morphology criteria alone.

to evaluate the clinical pregnancy rate (pregnancy defined as fetal heartbeat at 6-8 weeks) with the adjunctive use of the hera system (hera system used with traditional morphological grading) with embryos already deemed suitable for transfer compared to trained embryologists using standard morphology criteria alone. to evaluate the performance and utilization of the hera system as an adjunctive embryo grading and prioritization tool in an embryology lab setting with trained embryologists.

Eligibility criteria:
inclusion criteria: 1. \>21 and \< 43 years of age 2. women undergoing in vitro fertilization treatment using their own eggs 3. at least 8 eggs retrieved 4. fertilization using only ejaculated sperm including donor sperm (fresh or frozen) 5. single embryo transfer (set) 6. willing to comply with study protocol and procedures and be able to speak english 7. willing to provide written informed consent exclusion criteria: 1. gestational carriers 2. use of re-inseminated eggs 3. use of donor eggs 4. history of cancer 5. fertilization using surgically removed sperm 6. transfer of multiple (more than one) embryos at once 7. participants undergoing ivf with intent to bank embryos (i.e. no intention of embryo transfer for at least 6 months following egg retrieval) 8. concurrent participation in another clinical study that might interfere with the study results in either study
to evaluate safety, tolerability and pharmacodynamics of dwrx2003 against covid-19 (in philippines)

Conditions: COVID-19 Patients

Summary: this study is designed to assess the safety and tolerability of single doses of dwrx2003 in covid-19 patients.


Eligibility criteria:
inclusion criteria: 1. between 18 and 65 years of age, inclusive at time of signing the icf. 2. subjects with low to moderate risk defined as news covid-19 infection as confirmed by reverse transcriptase polymerase chain reaction (rt-pcr) assay 72 hours prior to clinical trial enrollment. exclusion criteria: 1. history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee). please note patients with allergies which can be managed without treatment can be included based on the decision of the investigator (or designee). 2. significant history, clinical manifestation of any medical disorder or any comorbid conditions which in the opinion of the investigator may interfere with the study
accumbofrontal tract study in 2 populations of patients with anorexia nervosa and obsessional compulsive disorder and healthy volunteer

Conditions: Accumbo Frontal Tract

Summary: restrictive anorexia nervosa and tocs are psychiatric diseases which shares a common pathophysiological substrate we hypothesize that anorexia patients and patients with ocd have structural and functional changes in the accumbofrontal tract. the main objective of this study will be to compare the structure and the connectivity of this tract in mri with diffusion sequences (dti tractography) and resting-state, in 3 distinct populations of anorexic patients, patients with ocd and healthy patients. the role of the accumbo-frontal tract in the cortico-striato-hypothalamo-cortical circuit seems to be established. dti tractography will allow the measurement of functional anisotropy (fa), a parameter that evaluates the diffusion of water molecules along the white matter fibers, and therefore the potential alteration of the studied tract. resting state sequences will allow to estimate the bold signal and the functionality of the tract.


Eligibility criteria:
inclusion criteria: * female patients * age between 18 and 65 years * subjects free to give their written consent for anorexia nervosa : * patients meeting the diagnostic criteria for anorexia nervosa according to dsm5 (american psychiatric association): low weight (\<85% of expected weight for age and height), fear of gaining weight or becoming fat, distortion of body image, and amenorrhea for more than 3 months * treatment with at least one antidepressant and one anxiolytic for ocd : * patients meeting the diagnostic criteria of ocds according to dsm5 (american psychiatric association) : presence of obsessions and / or compulsions, resulting in clinically significant suffering (loss of at least one hour per day) or impairment at the social, occupational level or in another important area of life. these symptoms are not due to the physiological effects of a substance or a general medical condition and cannot be better explained by the symptoms of another psychiatric disorder. * patients with homogeneous ocd in obsession and compulsion. * normal weight compared to expected weight for age and height * treatment with at least one antidepressant and one anxiolytic forhealthy volunteer •normal weight compared to expected weight for age and height exclusion criteria: * male * age \ 65 years * pregnancy * absence of free and informed consent signature * current processing by rtms * somatic intercurrent pathologies: neurological, cardiological, pneumological, renal, hepatic, endocrine, metabolic disorders ... * mental retardation (wais-iv qi \<70) * primary amenorrhea * absolute contraindication or relative to the realization of a magnetic resonance imaging without injection of contrast medium * old or intercurrent psychotic pathology
evaluation of prucalopride in subjects with moderate and severe hepatic impairment

Conditions: Hepatic Impairment

Summary: this is a single centre, open-label phase i trial to investigate the effects of moderate to severe hepatic impairment on the pharmacokinetics of prucalopride in comparison with healthy volunteers. furthermore the short-term safety and tolerability of a single dose of prucalopride will be assessed.

in this phase i trial two groups of 6 to 8 hepatically impaired subjects will be evaluated. the first group are the moderate hepatic impairment (grade b) subjects and the second group the severe hepatic impairment (grade c) subjects. subjects for both groups will be recruited and treated in parallel. after all subjects with hepatic impairment completed the treatment a third group with matching healthy volunteers will be recruited. eight healthy subjects will be selected matching for age, gender and weight (bmi based). the subjects will receive a single dose of 2 mg prucalopride in the morning after overnight fasting followed by the consumption of a standard breakfast after 2 hours. pharmacokinetic evaluation of blood samples will be done immediately before and at a specific timepoint up to 120h post-dosing. urine samples will be taken to determine prucalopride. adverse events, including serious adverse events, will be reported from signing the informed consent until the last visit. safety blood samples and a urine sample for urinalysis will be taken.

Eligibility criteria:
inclusion criteria: * main inclusion criteria for hepatic impairment subjects: * moderate (grade b) or severe (grade c) chronic hepatic impairment according to child-pugh classification; hepatic impairment must be stable, both clinically and biochemically; * within the normal range of body height and weight on the basis of the body mass index. * main inclusion criteria for healthy subjects: * matching on sex, age and weight(bmi based). exclusion criteria: * history or suspicion of barbiturate, amphetamine or narcotic abuse; suspicion of current alcohol abuse; * clinical suspicion or laboratory evidence of unstable hepatic impairment or acute liver injury; * clinically relevant renal disease as judged by the investigator.

Keywords: two groups of 8 hepatically impaired subjects, one group of 8 matched healthy subjects
use of a hypertension tool to manage blood pressure in hemodialysis

Conditions: Hypertension

Summary: the objective of this project is to develop, validate, and implement a tool to help manager hypertension in patients on hemodialysis.


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * receiving in-centre hd for at least 3 months * considered hypertensive based on a median intradialytic blood pressure ≥ 140/90 mmghg exclusion criteria: * are unable to provide informed consent * are deemed medically unstable by the primary physician
evaluation of the safety, tolerability and pharmacokinetics of repeat oral doses of gsk580416

Conditions: Bacterial Infection; Infections, Bacterial

Summary: this study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of gsk580416 and when co administered with ketoconazole, a pgp/cyp3a4 inhibitor.

a three part study in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of repeat escalating oral doses of gsk580416; the safety, tolerability, and pharmacokinetics of gsk580416 following a loading dose regimen; and the effect of ketoconazole on the pharmacokinetics of gsk580416

Eligibility criteria:
inclusion criteria: * healthy adults (as determined by medical evaluation including history, physical exam, vital signs, laboratory tests, and cardiac monitoring) * aged 18-60yrs, with bmi of 19-31kg/m2. * females must be of non-childbearing potential. * qtc \< 450 msec at screening. * subjects must be able to give consent and comply with restrictions of study. exclusion criteria: * clinically significant cns, cardiac, pulmonary, metabolic, renal, hepatic or gi condition or history that may place the subject at an unacceptable risk or may interfere with absorption, distribution, metabolism, or excretion of drug. * positive urine drug screen. * positive urine test for alcohol. * positive hiv or hep b and/or c assay. * history of regular tobacco use within 3 monts prior to screening or cotinine levels indicative of smoking at screening. * history of regular alcohol consumption (14 units/week for women and 21 units/week for men). * history of drug abuse or dependence within 12 months of study. * participation in another drug trial within 30 days of first dose. * exposure to more than 4 new chemical entities within 12 months of first dose. * use of prescription and non-prescription drugs including vitamins, dietary supplements, herbals within 7 days of first dose or st. john's wort within 28 days of the first dose. * consumption of red wine, seville oranges, grapefruit, or grapefruit juices within 14 days of first dose. * donation of blood in excess of 500 ml within 56 days of dosing. no blood donation is allowed 30 days prior to study participation. * a positive immunochemical fecal occult blood test at screening. * history of sensitivity to any of the study medications. * history of sensitivity to heparin or heparin-induced thrombocytopenia. * history of orthostatic hypotension or orthostatic hypotension at screening.

Keywords: gsk580416 ketoconazole interaction pleuromutilin oral dose